Press Releases argenx SE

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Real-time Euronext Bruxelles Other stock markets 13:51:47 12/02/2026 GMT			5-day change	1st Jan Change
705.80 ^EUR	+0.71%		-1.42%	-1.53%

02-10	European Equities Traded in the US as American Depositary Receipts Little Changed in Tuesday Trading	MT
02-06	European Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading; Little Changed for the Week	MT

Press Releases

01-13	Argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG	GL
01-13	Argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG	AQ
01-12	Argenx Highlights 2026 Strategic Priorities	GL
01-12	Argenx Highlights 2026 Strategic Priorities	AQ
01-06	Argenx to Present at 44th Annual J.P. Morgan Healthcare Conference	GL
01-05	Argenx Announces Leadership Transition Marking Next Evolution of Growth	GL
12-15	Argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease	GL
12-15	Argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease	AQ
11-18	Argenx Announces Results of Extraordinary General Meeting of Shareholders	GL
11-06	Argenx : FMR LLC - argenx SE - Breda	PU
11-05	/C O R R E C T I O N from source -- argenx Canada Inc./	AQ
30/10/25	Argenx : argenx Reports Third Quarter 2025 Financial Results and Provides Business Update	PU
30/10/25	Argenx : argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients	PU
30/10/25	Argenx Reports Third Quarter 2025 Financial Results and Provides Business Update	GL
29/10/25	Argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients	GL
23/10/25	Argenx : argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025	PU
23/10/25	Argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025	GL
23/10/25	Argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025	AQ
15/10/25	Argenx : argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session	PU
15/10/25	Argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session	GL
03/10/25	Argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025	GL
02/10/25	Argenx : Norges Bank - argenx SE - Breda	PU
01/10/25	Argenx : Breda	PU
25/09/25	Argenx : FMR LLC - argenx SE - Breda	PU
10/09/25	Argenx : FMR LLC - argenx SE - Breda	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Press Releases argenx SE

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Press Releases

Filters